SpringWorks Therapeutics
Clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 3417 % | 65 % | 81 % | 21 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (6267 %) | (143 %) | (52 %) | 2 % | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (5968 %) | (135 %) | (91 %) | (15 %) | 11 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 2763 % | 105 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
SpringWorks Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with rare diseases and cancer. The company employs a precision medicine approach, which means they tailor treatments based on the genetic and molecular profile of the disease. This approach aims to improve the efficacy and safety of treatments for underserved patient populations suffering from devastating conditions.
SpringWorks operates in the biopharmaceutical market, targeting both rare diseases and oncology. Their business model involves acquiring, developing, and commercializing innovative therapies. Revenue is generated through the successful development and commercialization of these therapies, often in collaboration with other pharmaceutical companies.
The company serves a niche market of patients with specific genetic profiles, offering them potentially life-changing treatments that are not widely available. SpringWorks is actively involved in clinical trials, including Phase 1b and 2 studies, to evaluate the efficacy and safety of their drug candidates.
Keywords: precision medicine, biopharmaceutical, rare diseases, cancer, clinical trials, genetic profiling, oncology, drug development, underserved patients, innovative therapies.